Obio Technology released its 2026 interim report, showing operating revenue of 122 million yuan, up 1.6 percent year on year, while net loss attributable to the parent company was 101 million yuan, narrowing from a loss of 105 million yuan in the same period last year. Second-quarter operating revenue was 71.25 million yuan, up 6.3 percent year on year, but the net loss attributable to the parent company was 48.33 million yuan, widening further from the same period last year. The company said revenue from its cell and gene therapy business was basically flat compared with the same period last year, while the CDMO business was affected by downstream investment and financing demand, and executed order prices remained at a relatively low level, resulting in a negative gross margin, though the overall loss showed a narrowing trend. As of the end of the second quarter, the company's total assets were 2.001 billion yuan, down 4.3 percent from the end of the previous year, and net assets attributable to the parent company were 1.308 billion yuan, down 7.1 percent from the end of the previous year.
OBiO Technology (Shanghai) Corp. Ltd. ANet loss widened in Q2 and CDMO business has negative gross margin due to low order prices.
